A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
We are doing a study to see if a new treatment called KRD or a new treatment called KRD+DARA can work better for people with multiple myeloma than the treatment everyone currently gets called VRD. We want to see if KRD or KRD+DARA are safer and more effective than VRD.
We are doing a study to see if a new treatment called KRD or a new treatment called KRD+DARA can work better for people with multiple myeloma than the treatment everyone currently gets called VRD. We want to see if KRD or KRD+DARA are safer and more effective than VRD.
*Third Opinion AI Generated Synopsis
Trial Summary
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: